Last reviewed · How we verify
Civamide
Civamide is a Small molecule drug developed by Winston Laboratories. It is currently in discontinued development. Also known as: oral civamide, zucapsaicin.
At a glance
| Generic name | Civamide |
|---|---|
| Also known as | oral civamide, zucapsaicin |
| Sponsor | Winston Laboratories |
| Target | Transient receptor potential cation channel subfamily V member 1 |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | discontinued |
Approved indications
Common side effects
Key clinical trials
- Randomized, Double-Blind, Placebo-Controlled Evaluation of the Tolerability of Two Civamide (Zucapsaicin) Patch Strengths Compared to Placebo Patch in Healthy Volunteers (Phase 1)
- A Two-Period Crossover Study to Compare the Systemic Exposure to Trans-Capsaicin and Cis-Capsaicin From an Intra-Articular Injection of CNTX-4975-05 (Trans-capsaicin for Injection) and Topical 8% Caps (Phase 1)
- A Phase III, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter Evaluation of Civamide (Zucapsaicin) Nasal Solution in the Treatment of Episodic Cluster Headache (Phase 3)
- A Phase 1 Open-Label, Single-Dose, Dose Escalation Study in Healthy Subjects to Evaluate the Safety and Pharmacokinetics of Orally Administered Civamide (Zucapsaicin) (Phase 1)
- A DOUBLE BLIND, RANDOMIZED, VEHICLE-CONTROLLED, PARALLEL-GROUP EVALUATION OF CIVAMIDE (ZUCAPSAICIN) 0.01% AND VEHICLE NASAL SPRAYS IN THE TREATMENT OF POSTHERPETIC NEURALGIA OF THE TRIGEMINAL NERVE (Phase 2)
- A Double-Blind, Randomized, Controlled, Parallel-Group, Multicenter Study Evaluating the Safety and Efficacy of Civamide Cream 0.075% as a Treatment in Subjects With Osteoarthritis of the Knee (Phase 3)
- A Phase II, Open-label, Tolerability and Efficacy Study of Civamide Nasal Solution, 0.01%, in Patients With Dry Eye Syndrome (Phase 2)
- A Phase III, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group, Multicenter Evaluation of Civamide Nasal Solution 0.01% in the Prevention of Cluster Headaches During an Episodic Cluster Hea (Phase 3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Civamide CI brief — competitive landscape report
- Civamide updates RSS · CI watch RSS
- Winston Laboratories portfolio CI
Frequently asked questions about Civamide
What is Civamide?
Civamide is a Small molecule drug developed by Winston Laboratories.
Who makes Civamide?
Civamide is developed by Winston Laboratories (see full Winston Laboratories pipeline at /company/winston-laboratories).
Is Civamide also known as anything else?
Civamide is also known as oral civamide, zucapsaicin.
What development phase is Civamide in?
Civamide is in discontinued.
What does Civamide target?
Civamide targets Transient receptor potential cation channel subfamily V member 1.
Related
- Target: All drugs targeting Transient receptor potential cation channel subfamily V member 1
- Manufacturer: Winston Laboratories — full pipeline
- Therapeutic area: All drugs in Other
- Also known as: oral civamide, zucapsaicin